Pulmozyme Access Solutions

Pulmozyme Access Solutions is a specialized patient support program managed by Genentech, a leading biotechnology company and a member of the Roche Group. The program is designed to assist patients in the United States with accessing Pulmozyme (dornase alfa), a recombinant human deoxyribonuclease I used to improve lung function in cystic fibrosis patients. Genentech Access Solutions provides comprehensive services including insurance benefits investigation, co-pay assistance for eligible patients, and patient assistance programs for those who are uninsured or underinsured. As a pioneer in the biotech industry, Genentech develops and manufactures a wide range of innovative therapies for serious or life-threatening medical conditions across oncology, immunology, and respiratory medicine.